Found: 18
Select item for more details and to access through your institution.
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 4, p. 481, doi. 10.1002/ajh.26480
- By:
- Publication type:
- Article
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e200, doi. 10.1016/j.clml.2019.09.334
- By:
- Publication type:
- Article
A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide- Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e201, doi. 10.1016/j.clml.2019.09.335
- By:
- Publication type:
- Article
A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e199, doi. 10.1016/j.clml.2019.09.333
- By:
- Publication type:
- Article
Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e3, doi. 10.1016/j.clml.2019.09.005
- By:
- Publication type:
- Article
Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e2, doi. 10.1016/j.clml.2019.09.004
- By:
- Publication type:
- Article
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 257, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
- Published in:
- EJHaem, 2021, v. 2, n. 1, p. 66, doi. 10.1002/jha2.129
- By:
- Publication type:
- Article
Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible.
- Published in:
- EJHaem, 2020, v. 1, n. 2, p. 481, doi. 10.1002/jha2.77
- By:
- Publication type:
- Article
Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Clinical Pharmacology, 2023, v. 89, n. 5, p. 1640, doi. 10.1111/bcp.15628
- By:
- Publication type:
- Article